Labcorp Holdings Inc. (NYSE: LH) hosted its 2026 Investor Day on September 10, 2026, where the company reaffirmed its full-year 2026 guidance and provided a long-term financial outlook through 2029. The event highlighted the company's strategy to drive growth through innovation in specialty testing, partnerships with health systems and pharmaceutical companies, personalized health solutions, and advanced technology.
Regarding the 2026 fiscal year, Labcorp affirmed its guidance, which was last updated on July 30, 2026. The company expects enterprise revenue between $14,710 million and $14,827 million, representing growth of 5.4% to 6.3% compared to 2025. This guidance assumes foreign exchange rates effective as of June 30, 2026, and includes the estimated impact from anticipated capital allocation, such as acquisitions, share repurchases, and dividends. Specific segments include Diagnostics Laboratories revenue projected between $11,450 million and $11,532 million (5.3% to 6.0% growth) and Biopharma Laboratory Services revenue between $3,269 million and $3,300 million (5.5% to 6.5% growth). The company also expects adjusted EPS to range from $18.10 to $18.55 and free cash flow between $1,240 million and $1,360 million.
In its long-term outlook through 2029, Labcorp projects compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to 11.5%. The company also anticipates adjusted operating margin expansion of 75 to 150 basis points by the end of 2029 and compound annual free cash flow growth in line with adjusted earnings growth.
